Mainz Biomed B.v. sell nvestor
Start price
11.11.23
/
50%
€2.14
Target price
11.11.24
€1.00
Performance (%)
-51.78%
End price
25.11.23
€1.03
Summary
This prediction ended on 25.11.23 with a price of €1.03. The SELL prediction by nvestor for Mainz Biomed B.v. performed very well with a performance of -51.78%. nvestor has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Mainz Biomed B.v. | 2.059% | 2.059% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
According to nvestor what are the pros and cons of Mainz Biomed B.v. for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
negative Cash Flow expected
Bad rating
Little Investments for future growth
Risky balance sheet
Increased challenges to pay loans and raise capital
Below average Management
Bad culture
Little innovation
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Significant cyclical dependencies
Little known brand
Business model of the past or high risk
Comments by nvestor for this prediction
In the thread Mainz Biomed B.v. diskutieren
Sell mit Kursziel 1,0
In the thread Trading Mainz Biomed B.v.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by nvestor for Mainz Biomed B.v.
Mainz Biomed B.v.
Start price
Target price
Perf. (%)
€1.03
25.11.23
25.11.23
€0.000
25.11.24
25.11.24
4.26%
09.12.23
09.12.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Mainz Biomed B.v.
Start price
Target price
Perf. (%)
€3.43
16.09.23
16.09.23
€1.00
16.09.24
16.09.24
-17.66%
30.09.23
30.09.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group